Ekso Bionics私募股权定价为590万美元

2026-01-21 22:06

Ekso Bionics (EKSO) on Wednesday said it entered into securities purchase agreements on Jan. 20, 2026, with institutional and accredited investors for a private placement of 5,852 shares of Series B preferred stock and warrants to buy up to 0.36M common shares.
Each preferred share has a stated value of $1,000 and may be converted at any time into common stock at $8.22 per share, representing 0.71M shares in total.
The company said the warrants will become exercisable six months after closing at $8.22 per share and will expire five years thereafter.
The offering is expected to close on or about Jan. 22, 2026, subject to customary closing conditions.
Gross proceeds from the private placement are expected to be about $5.9M, with net proceeds to be used for working capital and general corporate purposes.
Shares -7.22%.

More on Ekso Bionics Holdings